NCT00478465 2022-05-27
Valganciclovir (Valcyte) for Chronic Fatigue Syndrome Patients Who Have Elevated Antibody Titers Against Human Herpes Virus 6 (HHV-6)and Epstein-Barr Virus (EBV)
Stanford University
Phase 1/2 Completed
Clinical Trials
7 trialsNCT01972035 2022-04-12
ValGanciclovir Versus ValAcyclovir for Viral Prophylaxis in Kidney Transplantation
University of Minnesota
Phase 2 Completed
NCT03296553 2022-01-27
Impact of Valganciclovir on Severe IRIS-Kaposi Sarcoma Mortality: an Open-label, Parallel, Randomized Controlled-trial.
National Institute of Cancerología
Phase 2 Completed
NCT00400322 2021-03-01
Efficacy and Safety of Valcyte® as an add-on Therapy in Patients With Malignant Glioblastoma and Cytomegalovirus (CMV) Infection
Karolinska Institutet
Phase NA Completed
NCT01441063 2020-10-27
Tocilizumab for KSHV-Associated Multicentric Castleman Disease
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT01255644 2015-07-21
VGCV-CLL
Medical University of Vienna
Phase 4 Completed
NCT00562770 2012-07-31
Oral Valganciclovir Versus Valacyclovir
M.D. Anderson Cancer Center
Phase 2 Completed